The
neuroprotective effect of
MCI-9042 (Mitsubishi Pharma Corporation) was investigated on
glutamate-induced retinal ganglion cell (RGC) death in vitro and on rat
retinal ischemia in vivo. RGCs were purified from
retinal cells isolated from 6-day-old Wistar rats and cultured in
serum-free media. After application of 25 microM
glutamate, the viability of RGCs treated with or without several
serotonin 2 (5-HT(2)) receptor antagonists:
MCI-9042, M-1 (a major metabolite of
MCI-9042),
ketanserin, and
LY-53857; was evaluated by
calcein-acetoxymethyl ester staining.
Retinal ischemia was induced by intraocular pressure (IOP) elevation (130 mmHg, 50 min). Rats were intraperitoneally injected with
MCI-9042 at a dose of 3, 30 mg/kg or base at 30 min before and just after
ischemia-reperfusion.
Retinal damages were evaluated by histology, morphometric analysis and electroretinograms (ERGs) recordings at 7 days after
ischemia-reperfusion. 25 microM
glutamate decreased the number of viable RGCs to about 60 to 65% of untreated RGCs.
MCI-9042, M-1,
ketanserin, and
LY-53857 significantly reduced
glutamate-induced RGC death at concentrations of more than 100 nM, 1 nM, 1 microM and 100 nM, respectively.
Ischemia-reperfusion caused thinning of the thickness between the inner plexiform layer and the outer plexiform layer and attenuation of a-and b-waves in ERG recordings. The
intraperitoneal injection of
MCI-9042 significantly reduced morphological and functional damages in
retinal ischemia. Our data demonstrate that 5-HT(2) receptor antagonists including
MCI-9042 and M-1 have the
neuroprotective effects in cultured RGCs and that
MCI-9042 protects against ischemic
retinal diseases.